ManpowerGroup reported Q3 2026 revenue of $4.84 billion, slightly below estimates, with adjusted earnings per share at $1.01 matching expectations. Revenue grew 4% year-over-year, driven by strong U.S. Manpower and improving Experis segments. The company announced a CEO transition: Becky Frankiewicz will succeed Jonas Prising on January 1, 2027, as part of long-term succession planning, with Prising moving to executive chair. This leadership change signals a strategic shift while maintaining operational continuity.
ManpowerGroup's Q3 2026 revenue reached $4.84 billion with a CEO transition announced. For readers following Industrials-sector US stocks on Pluang, here is the market snapshot as of Oct 16, 2026 02:03 WIB: out of 136 priced stocks, 92 rose and 44 fell. Notable movers include Hafnia Limited Common Shares at USD 10.11 (-4.98%), Symbotic Inc at USD 39.75 (+4.88%) with 87% sell order activity, and Comfort Systems USA Inc at USD 1,469.61 (-4.67%) with 95% sell order activity.
Kohl's Chief Legal and Corporate Affairs Officer Jennifer J. Kent sold 18,352 shares for $403,744 on October 15, 2026, reducing her stake to 211,512 shares. Market opinions on Kohl's stock are divided, with some analysts expecting a decline while oth...
Copper exploration in British Columbia is increasingly relying on induced polarization (IP) geophysical surveys, which measure electrical chargeability and resistivity in rocks to identify sulphide mineralization associated with copper deposits. Gold...
The S&P 500 index has increased by 30.6% during the first 20 months of Donald Trump's second presidential term, slightly surpassing the 28.5% gain recorded in the same period of his first term. This comparison is significant for investors as it provi...
FMC sharply cut its Q3 2026 revenue forecast to $65-$125 million from $840-$900 million and now expects an adjusted EBITDA loss of $510-$565 million, down from a prior profit forecast. The company cited weak demand and excess inventories of higher-pr...
Citigroup increased its price target for Krystal Biotech to $416 from $386, citing strong Q2 revenue of $119.2 million from its approved product Vyjuvek and encouraging early clinical data for KB113, a treatment for basal cell carcinomas in Gorlin sy...
